Page last updated: 2024-12-05

isonicotinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

isonicotinic acid : A pyridinemonocarboxylic acid in which the carboxy group is at position 4 of the pyridine ring. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5922
CHEMBL ID1203
CHEBI ID6032
SCHEMBL ID1108
MeSH IDM0011774

Synonyms (76)

Synonym
.gamma.-picolinic acid
nsc1483
4-pyridinecarboxylic acid
nsc-1483
4-carboxypyridine
pyridine-4-carboxylic acid
p-pyridinecarboxylic acid
gamma-pyridinecarboxylic acid
CHEBI:6032 ,
gamma-picolinic acid
acide iso-nicotinique [french]
ai3-19239
1,4-dihydroisonicotinic acid
einecs 200-228-2
4-picolinic acid
AC-907/25014347
OPREA1_749724
BPBIO1_001365
BIOMOL-NT_000289
isonicotonic acid
inchi=1/c6h5no2/c8-6(9)5-1-3-7-4-2-5/h1-4h,(h,8,9
55-22-1
C07446
isonicotinic acid
isonicotinic acid, 99%
NCGC00163295-01
.gamma.-pyridinecarboxylic acid
CHEMBL1203
AKOS000118918
BMSE000133
I0207
NCGC00163295-02
tox21_200502
dtxcid80757
NCGC00258056-01
dtxsid8020757 ,
cas-55-22-1
A830537
STL168892
y8syn761tq ,
acide iso-nicotinique
unii-y8syn761tq
FT-0627430
FT-0627426
FT-0627428
AB00757
MN1 ,
S6014
AM81318
SCHEMBL1108
isonicotinic acid [who-dd]
isoniazid impurity a [ep impurity]
isonicotinic acid [mi]
W-105578
isonicotinicacid
STR00113
BS-3754
.alpha.-picolinic acid
pyridinecarboxylic acid-(4)
mfcd00006429
163751-04-0
isonicotinic-d4 acid
F2191-0075
isonicotinic acid, purum, >=99.0% (t)
isonicotinic acid, saj special grade, >=99.0%
pyridine-4-carboxylic acid (isonicotinic acid)
pyridine-4-carboxylic acid; nicotinic acid imp. e (ep); isonicotinic acid; isoniazid impurity a; nicotinic acid impurity e
SY002246
Q410465
HY-I0736
CS-W020040
isonicotinic acid; isoniazid, 4-pyridinecarboxylic acid, p-pyridinecarboxylic acid, 4-picolinic acid
S3V ,
AC8088
4-pyridine-carboxylic acid
EN300-19169

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
algal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyridinemonocarboxylic acidA monocarboxylic acid in which the carboxy group is attached to a pyridine (or substituted pyridine) ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency72.95310.007215.758889.3584AID1224835
GLI family zinc finger 3Homo sapiens (human)Potency28.05750.000714.592883.7951AID1259369
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency55.98200.003041.611522,387.1992AID1159552
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency41.61620.001530.607315,848.9004AID1224841; AID1224848; AID1224849
estrogen nuclear receptor alphaHomo sapiens (human)Potency55.98200.000229.305416,493.5996AID1259244
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency55.98200.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency55.98200.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nicotinate phosphoribosyltransferaseHomo sapiens (human)Ki0.00080.00000.00060.0019AID1618606
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
response to oxidative stressNicotinate phosphoribosyltransferaseHomo sapiens (human)
NAD salvageNicotinate phosphoribosyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
nicotinate phosphoribosyltransferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
protein bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
transferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
metal ion bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
extracellular regionNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
azurophil granule lumenNicotinate phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1149235Antibacterial activity against Mycobacterium tuberculosis assessed as growth inhibition at pH 71976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Mode of action and quantitative structure-activity correlations of tuberculostatic drugs of the isonicotinic acid hydrazide type.
AID1848086Antimycobacterial activity against Mycobacterium bovis BCG Pasteur ATCC35734 assessed as inhibition of bacterial growth incubated for 5 days by broth microdilution method2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents.
AID1149238Dissociation constant, pKa of the compound1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Mode of action and quantitative structure-activity correlations of tuberculostatic drugs of the isonicotinic acid hydrazide type.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1149234Antibacterial activity against Mycobacterium tuberculosis using acidic culture media at pH 5.9 assessed as growth inhibition1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Mode of action and quantitative structure-activity correlations of tuberculostatic drugs of the isonicotinic acid hydrazide type.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (42.86)24.3611
2020's3 (42.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.82 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index73.33 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (50.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]